Manuel J. Rial

ORCID: 0000-0003-4706-6608
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Asthma and respiratory diseases
  • Allergic Rhinitis and Sensitization
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Respiratory and Cough-Related Research
  • Food Allergy and Anaphylaxis Research
  • Contact Dermatitis and Allergies
  • Dermatology and Skin Diseases
  • Delphi Technique in Research
  • Occupational exposure and asthma
  • MicroRNA in disease regulation
  • Drug-Induced Adverse Reactions
  • Urticaria and Related Conditions
  • Occupational Health and Safety Research
  • Neonatal Respiratory Health Research
  • Eosinophilic Esophagitis
  • Pharmaceutical studies and practices
  • Pediatric health and respiratory diseases
  • Extracellular vesicles in disease
  • Respiratory Support and Mechanisms
  • Inhalation and Respiratory Drug Delivery
  • Immune Cell Function and Interaction
  • Acute Myeloid Leukemia Research
  • Bone and Joint Diseases
  • Occupational and environmental lung diseases
  • IL-33, ST2, and ILC Pathways

Complexo Hospitalario Universitario A Coruña
2016-2025

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
2018-2025

Instituto de Salud Carlos III
2018-2024

Universidade da Coruña
2020-2024

Instituto de Investigación Biomédica de A Coruña
2024

Hospital La Paz Institute for Health Research
2019-2023

Hospital San Juan de la Cruz
2022-2023

Hospital Universitario La Paz
2023

Hospital Clínic de Barcelona
2023

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2023

J. Sastre Astrid Crespo‐Lessmann Antonio Fernández‐Sánchez Manuel J. Rial Vicente Plaza and 95 more Francisco Callejas Gonzalez J. Lopez M. Martínez Riaza M. Moscardó Orenes P. Prieto Montaño M. Torrecillas Toro Carmen Andreu Balaguer M. Antón Gironés C. Baeza Martinez I. Flores Martín Purificación González‐Delgado M. Martos Calahorro G. Mediero Carrasco R. Rodríguez Pacheco Vanessa Tomas M. Mota Godoy J. Zapata Yébenes O. Villarreal Balza De Vallejo J. Alvarez Fernandez Teresa Bazús González G. Castaño De Las Pozas Carmen Díaz Donado S. Díaz Angulo G. Gala Ortiz B. Requejo Mañana R. Blanco Gonzalez E. Gómez Nieves Javier Torrado M T Dordal J. Juanola Ramón Lleonart Bellfill Josie Velasco Ester Pinto Nogués Marisa Rivera Ortún P. Rubinstein Aguñin N. Subira Farre Joan Valldeperas Combas Ignacio Ansotegui Zubeldia G. Bernaola Hortigüela J. Ciruelos Ayuso G. González Álvarez Manuel Peña Adoración Castro Paula Losada Llorente P. Marin Martinez N Marina Malanda Fernando Gonzalez T. Peña Miguel Manuel Hernández‐Guerra S. Jimenez Timon S. Porcel Carreño Michael Alwakil Olbah Aurelio Arnedillo Muñoz J. Chamorro Mohedad D. Gutierrez Fernandez Alvaro Camacho Conde López Marianela González Sanchís-Bayarri Bernal Luis Fernández Pellon E. Morchon Miguel Félix Ortiz Portal A. Suárez Rodríguez M. Modesto Alapont Isabela Raducan M. Salvador Segarra Pedro Bonilla P. Mata Calderon M. Mena Rodriguez R. Martínez Magdalena Martín Pérez M. Morales Villarejo Marina Blanco–Aparicio María‐Luisa Joga L. Fontan Garcia-Boente Vanesa García-Paz Francisco Javier González‐Barcala Ramón Nuñez Orjales Carlos Rábade Melissa Diaz Ana María Moreno‐Fernández S. Aparicio Español A. Ruiz San Francisco Bernardino Alcázar Navarrete L. Cassini Gomez De Cadiz Marie Rodriguez Juan F. López M. Lara Jiménez Julián López Caballero M. Martínez Ceres R. Mayorgas Costoya C. Morales García M. Rojas Vilchez Angela Ortiz J. Beitia Mazuecos

10.1016/j.jaip.2018.02.002 article EN The Journal of Allergy and Clinical Immunology In Practice 2018-02-14

There is a lack of consensus over the description and severity assignment allergic adverse reactions to immunotherapy, although there seems be at least in terms using World Allergy Organization (WAO) grading systems describe local events for Sublingual Immunotherapy (SLIT) Systemic Allergic Reactions (SARs) Subcutaneous (SCIT) amongst major national/regional allergy societies. In this manuscript, we propose modification previous WAO Grading system SARs, which aligns with newly-proposed...

10.1016/j.waojou.2024.100876 article EN cc-by World Allergy Organization Journal 2024-02-10

Asthma is a syndrome characterized by airway inflammation and obstruction. Due to its heterogeneity, the difficulties in asthma diagnosis treatment make discovery of new biomarkers focus research. So, we determined differential miRNA expression eosinophils between healthy asthmatic patients establish differentially expressed profile detectable sera for use as biomarker.MicroRNAs from peripheral subjects were isolated analyzed next-generation sequencing confirmed quantitative PCR 29...

10.1111/all.13570 article EN Allergy 2018-07-25

Clinical Implications•This study aimed to determine the rate of severe acute respiratory syndrome coronavirus 2 infection in Spanish patients with asthma under biological treatment and examine whether rates severity differ among several antiasthma drugs between without biologicals. With data from this cohort, we hypothesize that for uncontrolled does not represent a risk factor disease 2019 or its there are no significant differences different biologic used. •This On March 11, 2020, World...

10.1016/j.jaip.2020.09.050 article EN other-oa The Journal of Allergy and Clinical Immunology In Practice 2020-10-09

Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic localized forms disease are typically treated glucocorticoids. The approval novel biologic therapies targeting the interleukin-5 pathway can help reduce use glucocorticoids (SGC) in eosinophilic risk SGC-related adverse effects (AEs). In this article, panel experts different medical specialties reviewed current...

10.3389/fimmu.2023.1310211 article EN cc-by Frontiers in Immunology 2024-01-05

10.18176/jiaci.0301 article EN Journal of Investigational Allergology and Clinical Immunology 2018-12-09

Abstract Background Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5) receptor (IL-5R), was used before marketing authorisation in Spain real world setting as part of an early-access programme (EAP) to treat patients with severe eosinophilic asthma prior insufficient response or intolerance anti-IL5 treatment (mepolizumab reslizumab). The objective this study is describe patient profile candidate for and assess benralizumab effectiveness. Methods This...

10.1186/s12890-021-01785-z article EN cc-by BMC Pulmonary Medicine 2021-12-01

There is currently enough evidence to think that miRNAs play a role in several key points asthma, including diagnosis, severity of the disease, and response treatment. Cells release different types lipid double-membrane vesicles into extracellular microenvironment, exosomes, which function as very important elements intercellular communication. They are capable distributing genetic material, mRNA, mitochondrial DNA, microRNAs (miRNAs). Serum miRNA screening was performed order analyze...

10.3390/ijms22073558 article EN International Journal of Molecular Sciences 2021-03-30

Severe eosinophilic asthma poses a serious health and economic problem, so new therapy approaches have been developed to control it, including biological drugs such as benralizumab, which is monoclonal antibody that binds IL-5 receptor alpha subunit depletes peripheral blood eosinophils rapidly. Biomarkers predict the response this drug are needed microRNAs (miRNAs) can be useful tools. This study was performed with fifteen severe asthmatic patients treated serum miRNAs were evaluated before...

10.3390/jpm11020076 article EN Journal of Personalized Medicine 2021-01-28

Chronic rhinosinusitis with nasal polyps (CRSwNP), which is characterized by partial loss of smell (hyposmia) or total (anosmia), commonly associated asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). CRSwNP worsens severity and quality life. The objective this real-world study was to determine whether biological treatments prescribed for severe can improve olfaction in patients CRSwNP. A further compare the improvement N-ERD non-N-ERD subgroups.We...

10.18176/jiaci.0812 article EN Journal of Investigational Allergology and Clinical Immunology 2022-04-12

<b><i>Background/Objective:</i></b> The objective of this study was to describe the molecular sensitization profile mite allergy in an area with a high environmental exposure house dust mites (HDM) and storage mites. <b><i>Methods:</i></b> Skin prick tests were performed standardized extracts (DIATER, Madrid, Spain). A specific commercial panel (MADx) for <i>Dermatophagoides pteronyssinus</i> (Dpt), farinae</i> (Dfar),...

10.1159/000523869 article EN International Archives of Allergy and Immunology 2022-01-01
Coming Soon ...